

Attorney Docket No.: 47234-0003
Application No. 10/500,841
Amendment Dated: December 15, 2006
Reply to Office Action Dated: June 15, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) ~~[[A]]~~ An isolated peptide or protein having a neovascularization action and containing a basic amino acid cluster region of β 1,6-N-acetylglucosaminyltransferase, wherein the basic amino acid cluster region contains at least an amino acid sequence of SEQ ID NO: 11.

Claims 2-3. Cancel.

Claim 4. (Currently Amended) The isolated peptide or protein according to Claim 1, wherein, in the basic amino acid cluster region, the number of basic amino acids accounts for greater than 30% ~~[[or more]]~~ of the total number of amino acids in said region.

Claim 5. (Currently Amended) The isolated peptide or protein according to Claim 1, wherein the basic amino acid cluster region contains at least an amino acid sequence as depicted in SEQ ID NO: 7 or an amino acid sequence obtained by modification of one or more amino acids in this amino acid sequence.

Claim 6. (Currently Amended) A neovascularization accelerator comprising containing the peptide or protein according to Claim 1, and a pharmaceutically acceptable carrier.

Claim 7. (Currently Amended) ~~The neovascularization accelerator according to Claim 6, wherein it is a~~ A wound healing agent or a preventing and/or therapeutic agent for arteriosclerosis comprising a pharmaceutically effective amount of the peptide or protein of claim 1 and a pharmaceutically acceptable carrier.

Claims 8-22. Cancel.

23. (Previously Presented) A method for accelerating neovascularization comprising administering an effective amount of the peptide or the protein of claim 1 to a mammal.

Attorney Docket No.: 47234-0003
Application No. 10/500,841
Amendment Dated: December 15, 2006
Reply to Office Action Dated: June 15, 2006

Claim 24. (New) An agent for preventing and/or treating arteriosclerosis containing a pharmaceutically effective amount of the peptide or protein as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.